Showing 5041-5050 of 6036 results for "".
- Vaccine Rollout On Track, Expect 300M Doses Through March: Fedshttps://modernod.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/If the initial success of the Pfizer-BioNTech rollout continues, and emergency use authorization (EAU) is granted to Moderna and Johnson & Johnson vaccines in development, Operation Warp Speed officials expect to have 300 million doses of COVID-19 vaccines to distribute across the United Stat
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- FDA Review Confirms Efficacy of Moderna’s mRNA-1273 Vaccine Against COVID-19https://modernod.com/news/fda-review-confirms-efficacy-of-modernas-mrna-1273-vaccine-against-covid-19/2478666/According to briefing documents released ahead of an FDA advisory panel meeting on December 17, agency staff concluded that the efficacy of Moderna’s candidate COVID-19 vaccine mRNA-1273 at preventing coronavirus infections 14 days after a second dose was consistent, at 94.1%, with results
- Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia/2478667/Eyenovia announced that the first set of patients has been enrolled in the company’s phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its Optejet dispenser, for the
- Optos Introduces Ultra-Widefield Imaging Advancementshttps://modernod.com/news/optos-introduces-ultra-widefield-imaging-advancements/2478659/Optos has announced the introduction of several advancements to its Ultra-Widefield (UWF) imaging devices. The Optos platform, which includes Daytona, California, Monaco, and Silverstone, is the only retinal imaging t
- Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease/2478661/Palatin Technologies announced positive results in its phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population after 2 weeks of dosing and at the 12-week visi
- Regenxbio Announces Dosing of First Patient in Phase 2 ALTITUDE Trial of RGX-314 for the Treatment of DRhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-altitude-trial-of-rgx-314-for-the-treatment-of-dr/2478651/Regenxbio announced that the first patient has been dosed in ALTITUDE, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR). “We are pleased to announce the first patient dosed in our ALTITUDE tr
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero
- EyeQue to Launch VisionCheck 2 Do-It-Yourself Smartphone Vision Testhttps://modernod.com/news/eyeque-to-launch-visioncheck-2-do-it-yourself-smartphone-vision-test/2478648/EyeQue announced the upcoming launch of EyeQue VisionCheck 2, a refraction device available for consumers to test their own vision and order new glasses from home. VisionCheck 2 is a lightweight optical smartphone attachment and mobile app. The test results are expr
- GenSight Biologics Announces Publication of Results from Lumevoq REVERSE Pivotal Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-3-trial/2478644/GenSight Biologics announced that the journal Science Translational Medicine has published results from the REVERSE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate stu